Eric Lefkofsky innovative fight against cancer

Eric Lefkofsky, co-founder of Groupon, MediaOcean, Echo Global Logistics, and InnerWorking has announced the other company he co-founded, Tempus has received another $ 80 million investment. New Enterprise Associates, Revolution Growth, Kingship Trust Co and T.Rowe Price Associates are the latest investors to provide funding according to Mr. Lefkofsky. Tempus has received $ 210 million, since 2015, and including the latest investment of $ 80 million brings the value of Tempus to $ 1.1 billion. Breaking the $ 1 billion mark, makes Tempus one of the few startups to successfully make the short list of Unicorn. Any startup that is worth $ 1 billion of higher is considered a Unicorn startup company. Eric Lefkofsky says the funding is used to hire talented new employees. Tempus adds about 30 new hires each month and currently employees about 400 people. Eric Lefkofsky thinks the slew of investors rushing to invest recognize the potential data analytics has on healthcare.

The global healthcare industry is experiencing a revolution in how healthcare is delivered. Technology has enabled healthcare to be administered in ways that was impossible only a few years ago. Specifically data collection, is the key to unlocking life changing solutions in the fight against cancer. Tempus is a data analytical company, that uses machine learning and artificial intelligence algorithms to identify data trends in order to create personalized healthcare plans, based on past medical history, current health states, and data from various healthcare related devices. Tempus has the potential of fight cancer at the molecular level specifically to fit the needs of each cancer patient. We are for the first time in human history at a point where technology and healthcare are integrating in way we to truly change the way we fight diseases, specifically cancer.

Eric Lefkofsky graduated from the University of Michigan, and also has a Juris Doctor from the University of Michigan. In 2006 Liz and Eric Lefkofsky founded the Lefkofsky Family Foundation, a private charitable organization that seek to add value to the lives of people in the community. The Lefkofsky Family Foundation attempts to delivery adequate education to, stimulate medical research, ensuring basic human rights for underserved communities, focusing on women and girls.

Eric Lefkofsky’s Facebook Page:

Dr. David Samadi’s Take on Surgery Versus Radiation Therapy to Treat Localised Prostate Cancer

Being diagnosed with prostate cancer is a traumatizing experience. Prostate cancer is a common cancer, ranking second to skin cancer regarding prevalence in American men. The American Cancer Society forecasts that 164,690 American men will receive the shocking news in the year that they have prostate cancer. Out of those who will be diagnosed with prostate cancer in 2018, about 29 thousand of them will succumb to prostate cancer.

Researchers have established that over 90 percent of prostate cancer patients are diagnosed with localized cancer, affecting only the prostate gland. Such patients have to choose between radiotherapy and surgery treatment regimens. Surgery, however, is proving to be a more effective prostate cancer treatment method if the recent study by Canadian researchers is anything to go by. The study titled “Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis,” was concluded on the note that indeed surgery is more superior to radiation therapy at treating localized prostate gland.

Dr. David Samadi, a Lenox Hill Hospital-based urologist, agrees with the Canadian study, adding that radiation therapy fosters the development of secondary cancers. Rectal and bladder cancers arise primarily because of mutations at cellular level nurtured by radiation therapy sessions. Dr. David Samadi uses the cases of Mitt Romney, Colin Powell, and John Kerry, who were diagnosed with prostate cancers and each chose surgical prostate removal procedures. They are presently in good health, prostate cancer free. In fact, rumors are rife that Romney is considering running for the U.S Senate seat in Utah when Orrin Hatch retires.

However, even with studies heaping praises on the effectiveness of surgery as a prostate cancer treatment regimen, Dr. David Samadi warns a lot could go wrong if surgical procedures are not administered correctly. Some of the leading complications include loss of urinary continence and altered sexual functionality.

Dr. David Samadi

He is the leading champion of early diagnosis and treatment of prostate cancer. Dr. David Samadi is well versed in all matters prostate cancer including open traditional, laparoscopic, and robotic prostate surgeries.

Dr. David Samadi is known as a celebrity doctor, a title he earned owing to his extensive media exposure. He was the host of “Sunday Housecall” on Fox News Channel starting in 2011 to 2016. He regularly leverages his online presence to dispense medical advice to Americans not only on prostate cancer but also the state of the health care industry and other pertinent issues.

Dr. David Samadi’s Social Media:

Onctotarget Leads the Way in Hope for Cancer Patients

When a patient is fighting the battle against cancer, there are many factors that must be taken into consideration to determine the likelihood that they will survive beyond five years. Some of those factors are the current state of the patient’s health at the time of cancer onset, family support systems, normal type of treatment, and the type of cancer. However, just as important, or even more so, is the hope the patient has that there is a chance they will succeed. Oncotarget, a peer-reviewed journal that spans the globe, has shown direct evidence that the more hope a patient has, the more likely they are to live longer than five years with cancer.

Oncotarget focuses many of its articles and research examining the consequences the cancer management programs have on the patient’s mindset. Should these programs increase hope, they review it and recommend it to other oncologists. If these programs decrease hope, they warn other oncologists not to adopt the program. Learn more about Oncotarget at

Recently, Oncotarget was able to recommend the new treatment for papillary thyroid carcinoma that Dr. Carmelo Nucero developed after decades of research. Before this new treatment, papillary thyroid carcinoma posed a problem to oncologists due to its nature to become resistant to vemurafenib. The drug vemurafenib is the most common and affordable drug to treat papillary thyroid carcinoma. When a patient can no longer get vemurafenib, the patient is as good as dead.

The reason that papillary thyroid carcinoma develops a resistance to vemurafenib is that the cancer is based on a mutated BRAF gene. This mutated BRAF gene causes the immune system to attack the drug that is trying to cure it. Follow Oncotarget on Linkedin.

Dr. Carmelo Nucero was able to conduct research in this area and found there is a way to get vemurafenib to bypass the body’s immune system. When vemurafenib is administered at the same time of palbociclib, then the body stops attacking vemurafenib.

Dr. Carmelo Nucero is hopeful that since both drugs are, FDA approved treatment will be greenlighted soon. Catch the full interview on Oncotarget’s podcast now available on iTunes today.


Clay Siegall Is Changing The Way That Cancer Is Being Dealt With

Clay Siegall is the co-founder, CEO, President, and Chairman of the Board of Seattle Genetics. He has training as a scientist who has studied targeted cancer therapies and built the company to help people through scientific discovery, diligent research, and developing helpful drugs. The company has made more than $350 million through partnerships with Pfizer, Genentech (Roche), GlaxoSmithKline, and AbbVie and continues to develop antibody-drug-conjugates (ADCs). Its first ADC product was ADCETRIS, which was approved by the FDA in 2011. This ADC has now reached a global audience has been approved for sale in over 65 countries.

Before helping to put together Seattle Genetics, during 1988 to 1991, Clay Siegal worked with the National Cancer Institute and the National Institutes of Health and also Bristol-Myers Squibb Pharmaceutical Research Institute for six years following this. He has 15 patents and has authored over 70 publications and also earned a Bachelor’s of Science in Zoology during his time with the University of Maryland and a Ph.D. from George Washington University in Genetics. He has received many different awards and a couple of these include the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year and the 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences.

Clay Seigall got into the business of creating ADCs because he has always had an interest in medicine and believes that technology can help the modern world overcome many different kinds of disease. His interest in helping to find treatment for cancer came from a family member who got the disease and then almost died from the conventional form of treatment; chemotherapy. This spurred him to began learning about other kinds of cancer treatment, which he found just as terrible, and it was then that he became motivated to find a better way to help people who suffered with cancer.

Clay Siegall also said that while money has not been the main motivation for his interest in fighting cancer, that it is nice to be able to be your own boss while working to help other people. He believes that it has been through hard work, rather than skill and talent, alone, that he has been able to become the success that he is today.